Oneness Biotech Co., Ltd.
Clinical trials sponsored by Oneness Biotech Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a new gel outperform standard care for diabetic foot ulcers? Results expected Sep 2026 (estimated)
- New metabolic drug SNS851 gets first human safety check Results expected Oct 2026 (estimated)
- New shot could tame tough eczema Results expected May 2027 (estimated)
-
New shot could tame tough eczema
Disease control Recruiting nowThis study tests a drug called FB825 in adults with moderate-to-severe atopic dermatitis (eczema). Participants receive five injections over 12 weeks, either FB825 or a placebo, to see if it improves skin symptoms like redness and itching. The goal is to find a new treatment opti…
Phase 2 • Sponsor: Oneness Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New asthma drug shows promise in early trial
Disease control Recruiting nowThis study tests whether a new drug, FB825, can help adults with moderate-to-severe allergic asthma. About 100 participants will receive either FB825 or a placebo. The main goal is to see if FB825 reduces asthma attacks over 24 weeks.
Phase 2 • Sponsor: Oneness Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New metabolic drug SNS851 gets first human safety check
Knowledge-focused Recruiting nowThis early-stage study is testing a new drug, SNS851, in 52 healthy adults to see if it is safe and how the body processes it. Participants will receive either the drug or a placebo by injection. The goal is to check for side effects, not to treat any disease.
Phase 1 • Sponsor: Oneness Biotech Co., Ltd. • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC